Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin Soft Capsules as Adjuvant Therapy for Hepatocellular Carcinoma Post-Resection
NCT07328828Phase 2Active, not recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Icaritin in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Mar 2024; status: active, not recruiting.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07328828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328828.